Close
CDMO Safety Testing 2026
Novotech

Clinical Trials

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations through digitisation, the Central Drugs Standard Control Organisation (CDSCO) has transitioned from offline to online acceptance of clinical trial applications for cell and gene therapies products (CGTP). The agency has also...

Adaptive RCTs: Transforming Clinical Trials for Efficiency

Randomised controlled trials (RCTs) have long been the gold standard of clinical trials, with the most robust evidence of safety and effectiveness of new medicines. But the traditional RCT modelโ€”characterised by strict protocols, predetermined sample sizes, and rigid timelinesโ€”is...

Big Data Integration Transforming Clinical Trials

In the years that have gone by, the big data integration within clinical trials has gone on to emerge as a very transformative forceย within the healthcare industry, especially in Asia. As Asia continues to experience fast economic growth, advancement...

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to change a lot because there is a growing need for new ways to help people with their health and because medical research is making progress. As the world changes, the...

Asiaโ€™s CROs VCs: Blurring Service Provider & Investor Roles

In a time characterized by accelerated innovation and ever-more complicated clinical environments, Asia is witnessing an invigorating shift in the role of Contract Research Organizations (CROs). Once seen as service organizations that assist in the pharmaceutical and biotech product...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the correct contract development and manufacturing organization (CDMO) is essential to having a successful trip through the process of making a pharmaceutical product. This choice is dependent on two crucial aspects:...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics, has announced U.S. FDA approval of AMVUTTRAยฎ (vutrisiran) for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. This approval makes AMVUTTRA the first and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป